glp-1 cardiovascular outcome trials The Big Trial of a drug (Wegovy) to Reduce Major Events SGLTi and GLP-1 in HF

The research, published in the Journal of Endocrinology and Metabolism, found that the peptide had no effect on serum IGF-1 levels, no negative effect on carbohydrate metabolism, and no anti-AOD-9604 antibodies were detected in any patients

Optimizing Timing Around Exercise Exercise creates controlled tissue damage that triggers repair processes

Unfortunately, treatment with the multi-strain probiotic VSL#3 in non-obese males ( Lactobacillus casei Shirota in patients with metabolic syndrome did not reduce the increased fasting plasma TMAO levels after a HFD (Tripolt et al., 2015)

Have inquiries about our BOOST services